EVOK Evoke Pharma, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

EVOK [NASD]

Evoke Pharma, Inc.

Healthcare | Drug Manufacturers - Specialty & Generic | USA

statements

Index	-	P/E	-	EPS (ttm)	-0.29	Insider Own	1.10%	Shs Outstand	24.99M	Perf Week	20.00%
Market Cap	124.46M	Forward P/E	-	EPS next Y	-0.13	Insider Trans	0.00%	Shs Float	23.73M	Perf Month	42.15%
Income	-7.00M	PEG	-	EPS next Q	-0.10	Inst Own	12.90%	Short Float	3.70%	Perf Quarter	260.84%
Sales	-	P/S	-	EPS this Y	29.90%	Inst Trans	-11.37%	Short Ratio	0.54	Perf Half Y	260.84%
Book/sh	-0.01	P/B	-	EPS next Y	56.70%	ROA	-	Target Price	-	Perf Year	489.65%
Cash/sh	0.33	P/C	15.56	EPS next 5Y	40.00%	ROE	-	52W Range	0.73 - 6.06	Perf YTD	218.52%
Dividend	-	P/FCF	-	EPS past 5Y	32.00%	ROI	-	52W High	-12.25%	Beta	1.94
Dividend %	-	Quick Ratio	1.20	Sales past 5Y	-	Gross Margin	-	52W Low	625.56%	ATR	0.35
Employees	5	Current Ratio	1.20	Sales Q/Q	-	Oper. Margin	-	RSI (14)	77.08	Volatility	13.06% 7.79%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.20	Prev Close	5.16
Shortable	Yes	LT Debt/Eq	-	Earnings	Aug 06 BMO	Payout	-	Avg Volume	1.63M	Price	5.32
Recom	2.00	SMA20	34.20%	SMA50	54.92%	SMA200	180.04%	Volume	197,940	Change	3.10%

Jun-22-20

Upgrade

H.C. Wainwright

Neutral → Buy

$10

Mar-05-19

Downgrade

H.C. Wainwright

Buy → Neutral

Mar-08-18

Reiterated

B. Riley FBR, Inc.

Buy

$10 → $5

Oct-19-17

Resumed

FBR & Co.

Buy

$10

Mar-16-17

Reiterated

Rodman & Renshaw

Buy

$6 → $9

Jan-30-17

Upgrade

Laidlaw

Neutral → Buy

Jan-05-17

Upgrade

Rodman & Renshaw

Neutral → Buy

$2.50 → $6

Dec-23-16

Reiterated

Rodman & Renshaw

Neutral

$2 → $2.50

Jul-19-16

Reiterated

FBR Capital

Outperform

$17 → $9

Jul-19-16

Downgrade

Noble Financial

Buy → Hold

Jul-18-16

Downgrade

Rodman & Renshaw

Buy → Neutral

Mar-16-16

Initiated

Northland Capital

Outperform

Mar-14-16

Reiterated

Ascendiant Capital Markets

Buy

$11 → $12

Feb-17-16

Resumed

FBR Capital

Outperform

$17

Dec-03-14

Reiterated

MLV & Co

Buy

$12.50 → $14

Nov-07-14

Initiated

MLV & Co

Buy

$12.50

Apr-22-14

Initiated

Laidlaw

Buy

$19

Nov-19-13

Initiated

Aegis Capital

Buy

$60

Aug-06-20 08:30AM	Evoke Pharma Reports Second Quarter 2020 Financial Results GlobeNewswire
Jul-15-20 08:30AM	Evoke Pharma Initiates Commercial Manufacturing of Gimoti GlobeNewswire
Jul-08-20 08:30AM	Evoke Pharma Extends Cash Runway to 2Q 2021 GlobeNewswire
Jun-25-20 10:58PM	Evoke Pharma Set to Gain 170%? This 5-Star Analyst Thinks So SmarterAnalyst +6.57%
Jun-22-20 10:23AM	Price Over Earnings Overview: Evoke Pharma Benzinga +61.70%
Jun-19-20 03:32PM	FDA Approves Evokes GIMOTI GlobeNewswire
May-20-20 08:30AM	Evoke Receives FDA Conditional Acceptance of Gimoti Brand Name Following NDA Resubmission GlobeNewswire +14.86%
May-12-20 08:30AM	Evoke Pharma Reports First Quarter 2020 Financial Results and Changes its 2020 Annual Meeting of Stockholders to a Virtual Format GlobeNewswire
Mar-12-20 08:30AM	Evoke Pharma Reports Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire -18.02%
Jan-27-20 08:30AM	Evoke Pharma Receives Notice of Allowance from USPTO for Gimoti GlobeNewswire
Jan-23-20 08:30AM	Evoke Pharma Enters Commercialization Agreement with EVERSANA Life Sciences for Gimoti GlobeNewswire +5.48%
Jan-22-20 10:00AM	Evoke Pharma's NDA Resubmission for Gimoti Gets FDA Acceptance Zacks
Jan-21-20 08:30AM	FDA Accepts Evoke Pharmas NDA Resubmission for Gimoti GlobeNewswire
Dec-20-19 08:30AM	Evoke Resubmits Gimoti New Drug Application to FDA GlobeNewswire
Dec-02-19 08:30AM	Evoke Pharma Regains Compliance with Nasdaq Minimum Bid Requirement GlobeNewswire
Nov-18-19 08:52AM	What Kind Of Shareholder Appears On The Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shareholder Register? Simply Wall St. +34.55%
Nov-13-19 08:30AM	Evoke Pharma Granted 180-Day Extension by Nasdaq Regarding Minimum Bid Price GlobeNewswire
Nov-07-19 08:30AM	Evoke Pharma Reports Third Quarter 2019 Financial Results GlobeNewswire
Sep-20-19 05:14PM	Foamix Initiates Phase II Study on Acne Combination Foam Zacks
Sep-19-19 12:02PM	When Will Evoke Pharma, Inc. (NASDAQ:EVOK) Come Back To Market? Simply Wall St.
10:29AM	Zynerba Releases Data on Epilepsy Candidate, Stock Down Zacks
Sep-17-19 08:30AM	Evoke Pharma Completes Manufacturing of Commercial Scale Registration Batches of Gimoti GlobeNewswire
Aug-08-19 05:30AM	Evoke Pharma to Resubmit Gimoti NDA Based on FDA Meeting Minutes and Announces Second Quarter 2019 Financial Results GlobeNewswire -8.03%
Jul-25-19 12:58PM	Biotech Stock On The Radar: Evoke Pharma Sets Date With FDA Benzinga -7.89%
Jul-11-19 11:31AM	Is Evoke Pharma, Inc. (NASDAQ:EVOK) A Volatile Stock? Simply Wall St.
Jun-27-19 08:30AM	Evoke Pharma Requests Type A FDA Meeting to Plan for Resubmission of Gimoti NDA GlobeNewswire +7.98%
May-08-19 04:05PM	Evoke Pharma Reports First Quarter 2019 Financial Results GlobeNewswire
11:39AM	Evoke Pharma (EVOK) to Post Q1 Earnings: What's in Store? Zacks
Apr-29-19 09:13AM	Investors Who Bought Evoke Pharma (NASDAQ:EVOK) Shares Five Years Ago Are Now Down 92% Simply Wall St.
Apr-15-19 12:08PM	Dr. Reddy's (RDY) Inks Deal to Acquire Portfolio of 42 ANDAs Zacks
Apr-03-19 08:19AM	The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings Benzinga
Apr-02-19 06:00AM	Evoke Pharma Receives Complete Response Letter and Recommendations to Address Deficiencies from FDA for Gimoti NDA GlobeNewswire -47.06%
Mar-29-19 12:45PM	Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates Benzinga +9.49%
Mar-14-19 08:30AM	Evoke Pharma Submits Response to FDA Review Letter for Gimoti NDA GlobeNewswire +17.50%
Mar-06-19 08:30AM	Evoke Pharma Reports Fourth Quarter and Full Year 2018 Financial Results and FDA Communication GlobeNewswire
Mar-04-19 08:30AM	Evoke Pharma Receives Preliminary FDA Communication on Gimoti NDA GlobeNewswire -57.24%
Feb-27-19 08:30AM	Evoke Pharma Schedules Conference Call and Webcast for Fourth Quarter and Full-Year 2018 Financial Results GlobeNewswire
Jan-07-19 08:30AM	Evoke Pharma Signs Commercial and Financial Agreement for its Lead Product Gimoti in the U.S. with Novos Growth Partners GlobeNewswire
Jan-04-19 07:56AM	Loss-Making Evoke Pharma, Inc. (NASDAQ:EVOK) Expected To Breakeven Simply Wall St.
Nov-13-18 04:05PM	Evoke Pharma Reports Third Quarter 2018 Results GlobeNewswire
Oct-16-18 10:32AM	Shareholders Should Check The Ownership Structure Of Evoke Pharma Inc (NASDAQ:EVOK) Simply Wall St.
Oct-08-18 06:28PM	Generic-Drugs Stock Outlook: No Respite from Pricing Issues Zacks
Sep-28-18 09:59AM	Forget Mylan, Invest in These 3 Generic/Drug Stocks Instead Zacks
Aug-17-18 09:12AM	Evoke Pharma (EVOK) Announces FDA Acceptance of Gimoti NDA Zacks
Aug-16-18 08:30AM	Evoke Pharmas Gimoti NDA Accepted for FDA Review GlobeNewswire
Aug-09-18 04:05PM	Evoke Pharma Reports Second Quarter 2018 Results and Recent Highlights GlobeNewswire
Jun-06-18 01:38PM	At $2.8701, Is Evoke Pharma Inc (NASDAQ:EVOK) A Buy? Simply Wall St.
Jun-04-18 07:30AM	Evoke Announces FDA Submission of New Drug Application for Gimoti GlobeNewswire
May-14-18 10:27AM	Evoke Pharma Inc (NASDAQ:EVOK) Is Expected To Breakeven Simply Wall St.
06:30AM	Evoke Pharma Reports First Quarter 2018 Results and Highlights GlobeNewswire
May-10-18 07:30AM	Evoke Granted Gender Specific Patent for Gimoti in Mexico GlobeNewswire
Apr-30-18 07:30AM	Evoke Granted First Gender Specific Patent for Gimoti GlobeNewswire
Mar-26-18 07:30AM	Evoke Announces Agreement with Mallinckrodt to Amend Milestone Payments GlobeNewswire
Mar-07-18 04:05PM	Evoke Pharma Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Highlights GlobeNewswire
12:00PM	Evoke Pharma, Inc. to Host Earnings Call ACCESSWIRE
Mar-06-18 07:30AM	Evoke Pharma to Present at the Upcoming Roth and Oppenheimer Investor Conferences GlobeNewswire
Mar-05-18 07:30AM	FDA Approves PDUFA Fee Waiver for Gimoti New Drug Application GlobeNewswire
Feb-21-18 08:30AM	Evoke Pharma Schedules Conference Call and Webcast for Fourth Quarter and Full-Year 2017 Financial Results GlobeNewswire
Feb-15-18 07:30AM	Evoke Announces Discovery of Sex-Based Pharmacokinetic Differences for Gimoti GlobeNewswire -14.81%
Dec-12-17 07:40AM	Wired News Akaris Phase-II COBALT Trial of Coversin in Patients with PNH Met the Primary Endpoint ACCESSWIRE
Dec-11-17 07:30AM	Wired News SteadyMed Reported FDA Agreed Pathway to Trevyent NDA Resubmission ACCESSWIRE
Nov-14-17 04:05PM	Evoke Pharma Reports Third Quarter 2017 Results and Highlights GlobeNewswire
12:00PM	Evoke Pharma, Inc. to Host Earnings Call ACCESSWIRE
06:49AM	A Look At Evoke Pharma Inc (EVOK) And The Healthcare Sector Simply Wall St.
Nov-09-17 08:30AM	Evoke Pharma Signs Commercial Agreement with Thermo Fisher Scientific GlobeNewswire
Nov-07-17 08:30AM	Evoke Pharma Schedules Conference Call and Webcast for Third Quarter 2017 Financial Results GlobeNewswire
06:33AM	Is It The Right Time To Buy Evoke Pharma Inc (EVOK)? Simply Wall St.
Oct-27-17 08:30AM	Evoke Pharma Announces Conference Call to Review the Successful Results of Comparative Exposure Pharmacokinetic Study for Gimoti GlobeNewswire
Oct-23-17 07:30AM	Evoke Pharma Announces Positive Topline Results from Comparative Exposure Pharmacokinetic Study for Gimoti GlobeNewswire
Oct-17-17 09:53AM	New Strong Sell Stocks for October 17th Zacks
Oct-04-17 08:30AM	Evoke Pharma to Participate in the Oppenheimer & Co. Specialty Pharmaceuticals Conference GlobeNewswire
Sep-12-17 08:30AM	Evoke Pharma Completes Dosing for Gimoti Comparative Exposure Pharmacokinetic Study GlobeNewswire
Sep-05-17 08:30AM	Evoke Pharma to Present at the 19th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire
Aug-14-17 04:05PM	Evoke Pharma Reports Second Quarter 2017 Results and Highlights GlobeNewswire
12:10PM	Investor Network: Evoke Pharma, Inc. to Host Earnings Call ACCESSWIRE
08:30AM	Evoke Pharma Initiates Comparative Exposure Pharmacokinetic Study for Gimoti GlobeNewswire
Aug-07-17 08:30AM	Evoke Pharma Schedules Conference Call and Webcast for Second Quarter 2017 Financial Results GlobeNewswire
May-31-17 08:30AM	Evoke Pharma Enters Agreement with Rho to Submit NDA for Gimoti GlobeNewswire
May-15-17 04:05PM	Evoke Pharma Reports First Quarter 2017 Results GlobeNewswire
03:00PM	Investor Network: Evoke Pharma, Inc. to Host Earnings Call Accesswire
May-10-17 08:30AM	Evoke Pharma Presents Gimoti Efficacy and Safety Data from Phase 3 Trial as Late Breaker at Digestive Disease Week 2017 GlobeNewswire
May-01-17 08:30AM	Evoke Pharma Schedules Conference Call and Webcast for First Quarter 2017 Financial Results GlobeNewswire
Apr-18-17 08:30AM	Evoke Pharma Announces Collaboration with Spaulding Clinical Research for the Gimoti Comparative Exposure Pharmacokinetic Trial GlobeNewswire
Apr-04-17 08:30AM	Positive Type A Meeting with FDA Confirms Acceptability of Evoke Pharmas Proposed Comparative Exposure PK Trial for Gimoti NDA GlobeNewswire
08:30AM	Positive Type A Meeting with FDA Confirms Acceptability of Evoke Pharmas Proposed Comparative Exposure PK Trial for Gimoti NDA
Mar-22-17 01:04PM	EVOKE PHARMA INC Financials
Mar-21-17 08:30AM	Evoke Pharmas Phase 3 Results for Gimoti Accepted as Late-Breaker for Presentation at Digestive Disease Week 2017 GlobeNewswire
Mar-15-17 04:12PM	EVOKE PHARMA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM	Evoke Pharma Reports Fourth Quarter and Full Year 2016 Results GlobeNewswire
07:07AM	Q4 2016 Evoke Pharma Inc Earnings Release - After Market Close
Mar-10-17 05:19PM	EVOKE PHARMA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar-07-17 08:30AM	Evoke Pharma Schedules Webcast and Conference Call for Fourth Quarter and Full-Year 2016 Financial Results GlobeNewswire
Mar-06-17 08:30AM	Evoke Pharma Announces Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Feb-16-17 04:15PM	EVOKE PHARMA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
09:30AM	Biotech Industry Poised for a Breakout in 2017? Today's Reports on Evoke Pharma and Novavax Accesswire
08:46AM	Evoke Pharma Announces Pricing of Public Offering of Common Stock GlobeNewswire
Feb-15-17 04:42PM	Evoke Pharma Announces Proposed Public Offering of Common Stock GlobeNewswire
10:55AM	Why Evoke Pharma Shares Are Exploding 24/7 Wall St.
10:55AM	Why Evoke Pharma Shares Are Exploding
08:49AM	Evoke Pharma's stock soars after FDA exempts Gimoti from HF Validation MarketWatch

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. The company was founded in 2007 and is headquartered in Solana Beach, California.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience